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Abstract: The brain-derived neurotrophic factor (BDNF) plays crucial roles in both the developing
and mature brain. Moreover, alterations in BDNF levels are correlated with the cognitive impairment
observed in several neurological diseases. Among the different therapeutic strategies developed to
improve endogenous BDNF levels is the administration of the BDNF-inducing drug Fingolimod, an
agonist of the sphingosine-1-phosphate receptor. Fingolimod treatment was shown to rescue diverse
symptoms associated with several neurological conditions (i.e., Alzheimer disease, Rett syndrome).
However, the cellular mechanisms through which Fingolimod mediates its BDNF-dependent
therapeutic effects remain unclear. We show that Fingolimod regulates the dendritic architecture,
dendritic spine density and morphology of healthy mature primary hippocampal neurons. Moreover,
the application of Fingolimod upregulates the expression of activity-related proteins c-Fos and
pERK1/2 in these cells. Importantly, we show that BDNF release is required for these actions
of Fingolimod. As alterations in neuronal structure underlie cognitive impairment, we tested
whether Fingolimod application might prevent the abnormalities in neuronal structure typical of
two neurodevelopmental disorders, namely Rett syndrome and Cdk5 deficiency disorder. We found
a significant rescue in the neurite architecture of developing cortical neurons from Mecp2 and Cdkl5
mutant mice. Our study provides insights into understanding the BDNF-dependent therapeutic
actions of Fingolimod.
Keywords: Fingolimod; FTY720; BDNF; primary cultures; dendrites; dendritic spines; Rett syndrome;
Mecp2; Cdkl5
1. Introduction
The secreted growth factor brain derived neurotrophic factor (BDNF) belongs to the Neurotrophin
family and is produced by neurons in an activity-dependent manner in all major brain areas [1].
It interacts with the tropomyosin receptor kinase B (TrkB) to accomplish its trophic and
plasticity-promoting activities. In the developing central nervous system (CNS), BDNF enhances cell
survival, promotes morphogenesis and differentiation, and contributes to the formation and maturation
of synapses [2]. In the mature CNS, BDNF is essential for activity-dependent synaptic plasticity,
regulating synaptic transmission, and maintaining the mature neuronal architecture, including
dendritic spine density, size and shape [3,4], as well as for learning and memory processes [5].
The expression of BDNF is tightly regulated and alterations in BDNF levels and function have been
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suggested to underlie both the cognitive decline during aging processes as well as the pathogenesis
of several neurological and psychiatric disorders [6–8]. While BDNF has been shown to exhibit
potent therapeutic effects, its delivery to the brain remains challenging due to its short half-life and
poor diffusion across the blood-brain-barrier. Current therapeutic strategies employ viral-mediated
Bdnf gene delivery or modulation of TrkB activity to promote BDNF-TrkB signaling. Alternatively,
the administration of BDNF-inducing drugs has been shown to rescue different neurological diseases
characterized by BDNF dysregulation. Of special interest in this context is the sphingosine-1-phosphate
analog Fingolimod, an immunomodulatory oral drug used in relapsing-remitting forms of multiple
sclerosis [9]. The pro-drug (Fingolimod) diffuses across the blood–brain barrier into the CNS
parenchyma where it is phosphorylated into its active form Fingolimod-P and acts as ligand to
a subset of Sphingosine-1-phosphate receptors (S1PR1 and 3–5) expressed, among others, also by
different brain cells [10]. Interestingly, Fingolimod has been shown to upregulate BDNF mRNA levels
and increase BDNF protein release both in vitro and in vivo in an activity- and MAPK-dependent
manner [11]. The functional significance of the Fingolimod-induced BDNF release is marked by its
ability to improve the cognitive impairment typical of different neurological diseases, e.g., Alzheimer’s
and Huntington’s diseases [12,13]. Furthermore, the rescue of typical symptoms upon Fingolimod
treatment was shown to be associated with improved synaptic plasticity and amelioration of dendritic
spine loss in the hippocampus of a mouse model for Huntington’s disease [13] and prevented spine
loss in the cortex during the acute phase of experimental acute encephalitis [14,15].
Rett syndrome (RTT) is an X-linked neurodevelopmental genetic disorder mainly due to loss
of the Mecp2 function resulting at the cellular level in impaired neurite outgrowth and abnormal
neuronal architecture [16,17] associated with the reduction of both BDNF mRNA and protein levels [18].
BDNF overexpression, its exogenous application, or TrkB agonistic activation have been shown to
restore synaptic plasticity, improve neuronal activity and structural aberrations in Mecp2 deficient mice,
mimicking the human disorder [18–20]. Moreover, Fingolimod administration increased BDNF levels
in the cortex, hippocampus, and striatum and significantly improved the motor deficits observed in
Mecp2 mutant mice [11]. Cdkl5 deficiency disorder (CDD), an X-linked atypical variant of RTT is also
characterized by impairment in neuronal morphology [21,22] and reduced BDNF mRNA levels [22].
Treatment with a specific TrkB agonist was shown to rescue the structural and functional impairments
in a Cdkl5 deficient mouse [23] indicating an important role of the BDNF-TrkB signaling in this context.
While Fingolimod has been established as a promising therapeutic agent for several disease
models, whether it is able to modulate the structure of mature, healthy CNS neurons is currently
not known. Here, we examine the ability of Fingolimod to modulate dendritic architecture in
a BDNF-dependent manner of primary wild type hippocampal neurons. Moreover, in our study, we
tested whether Fingolimod application can rescue structural anomalies in cortical neurons of Mecp2
and Cdkl5 mutant mice.
2. Results
2.1. Fingolimod-Phosphate (FTY720-P) Modulates Dendritic Architecture of Mature, Healthy Hippocampal
Neurons
To address a potential role of Fingolimod-phosphate (FTY720-P) in modulating the dendritic
architecture of healthy hippocampal neurons, 21 DIV primary hippocampal cultures were treated for
24h with 10 nM FTY720-P or DMSO, as control. The Sholl analysis, performed on feGFP expressing
hippocampal neurons, showed a significantly higher dendritic complexity upon FTY720-P treatment
when compared to controls (Figure 1A). The increase in dendritic complexity was found to be statistically
significant specifically for the portion of the dendritic tree closer to the cell soma (Figure 1A,B; two-way
ANOVA F1,4560 = 87.78, p < 0.0001). Accordingly, a significant increase was observed in the total
number of dendritic intersections (Figure 1C; two-tailed unpaired t-test: t = 2.710, df = 6, p < 0.01;
DMSO: 330.8 ± 13.10 vs, FTY720-P: 383.4 ± 14.20) as well as in the total dendritic lengths of FTY720-P
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treated neurons compared to controls (Figure 1D; two-tailed unpaired t-test: t = 2.820, df = 76, p < 0.01;
DMSO: 3867 ± 142.9 vs. FTY720-P: 4488 ± 166.0).
Figure 1. Fingolimod-phosphate (FTY720-P) modulates neuronal morphology in mature hippocampal
neurons. FeGFP expressing 21DIV primary hippocampal neurons from healthy wild type BL/6J mice
were treated with 10nM FTY720-P for 24h. (A) Representative images (left) of feGFP expressing neurons
treated with DMSO (above, black) and 10nM FTY720-P (below, magenta) and the relative Neurolucida
tracing used to perform the Sholl analysis (right). Scale bar: 100µm. (B) Sholl analysis displaying
dendritic complexity plotted against distance from the cell soma. F value refers to the DMSO v/s
FTY720-P comparison. The graphs show (C) the total dendritic complexity and (D) total lengths of
dendrites for the DMSO (black) and FTY720-P (magenta) treated neurons. (E) Representative segments
of secondary dendrites from feGFP transfected neurons used to analyze dendritic spine density. Scale
bar: 5µm (F) Graphical representation of the spine density for neurons treated with 10 (magenta solid)
or 100nM (magenta open) FTY720-P their respective DMSO controls (10nM black solid; 100nM black
open). (G) the graph shows the distribution of different dendritic spine types across all treatment
groups. The four different types of spines– mushroom (M), thin (T), stubby (S) and filopodia (F)
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as represented in the schematic, were quantified and represented as a fraction of total spines for neurons
treated with FYT720P (10 nM magenta solid; 100nM magenta open) or DMSO (10 nM black solid;
100nM black open). (H) Images of fields of view (FOV) of DMSO (left) and FTY720-P (right) treated
primary hippocampal cultures immunostained for c-Fos (inset: above) and MAP2 (inset: below) with
their respective merged images (right). The arrows indicate c-Fos expressing MAP2 positive neurons
in the merged picture. Scale bar: 100µm. (I) Graph comparing the normalized number of c-Fos+
cells over total MAP2+ neurons between DMSO (black) and FTY720-P (magenta) treated cultures.
All plots represent data as mean + SEM. Numbers in the bars indicate total number of neurons or of
FOV analyzed, obtained from ≥3 sets of independent experiments. Two-way ANOVA followed by
Bonferroni post-hoc test was used in (B) and (G). For (C,D) and (I) unpaired Student’s t-test and for (F),
one-way ANOVA with Bonferroni post-hoc was used. Significance is denoted as ** p < 0.01, *** p <
0.001, **** p < 0.0001.
Next, to determine if FTY720-P also influences dendritic spines number, dendritic spine density
was quantified on secondary dendritic branches of control and FTY720-P treated neurons (Figure 1E).
We observed a significant increase (~10%) in the number of dendritic spines per µm in the FTY720-P
group (Figure 1E,F; two-tailed unpaired t-test: t = 2.669, df = 76, p < 0.01; DMSO: 1.027 ± 0.0283,
FTY720-P: 1.137 ± 0.0299). Subsequently, a possible concentration-dependent activity of FTY720-P
in regulating dendritic spine density was tested by treating primary hippocampal cultures with
a 10-fold higher concentration of FTY720-P (100 nM) or its respective DMSO control. The analysis
revealed that, in comparison to the control, the higher drug concentration significantly enhanced
spine density by ~20% (Figure 1E,F; two-tailed unpaired t-test: t = 4.369, df = 82, p < 0.0001; DMSO:
1.071 ± 0.0334, FTY720-P_100nM: 1.289 ± 0.0373). Next, a possible concentration-dependent role of
FTY720-P was tested in modulating dendritic spine morphology. For this purpose, dendritic spines
were structurally classified into four subtypes-mushroom, thin, stubby or filopodia-like (Figure 1G,
schematic) based on their length and their head-to-neck ratios [24]. While the neurons treated with
lower FTY720-P concentration (10 nM) did not show any difference in their spine-type distribution
compared to the relative control neurons, treatment with higher FTY720-P concentration (100 nM)
showed a significant increase in the proportion of mushroom-type spines (Figure 1E,G; p < 0.0001;
DMSO: 0.591± 0.027 vs. FTY720-P: 0.735± 0.023) associated with a significant decrease in the proportion
of thin spines (Figure 1E,G; p < 0.001; DMSO: 0.353 ± 0.023 vs. FTY720-P: 0.233 ± 0.021). The fraction
of stubby and filopodia-like spines remained unchanged across all treatment groups (Figure 1E,G).
Overall, these observations indicate that, in mature primary hippocampal neurons, a 24-h treatment
with FTY720-P results in a mild increase in the dendritic complexity, particularly at the proximal
dendrites and in total dendritic length. Moreover, a FTY720-P treatment affects the dendritic spine
density and structure in a concentration-dependent manner, with the higher concentration inducing an
increase in the proportion of mature dendritic spines.
2.2. Fingolimod-Phosphate induces the Expression of the Activity-Related Immediate Early Gene c-fos
FTY720-P has been shown to positively modulate network activity of cultured cortical neurons by
promoting excitatory and suppressing inhibitory synaptic transmission signaling via the S1PR1 [11].
Moreover, treatment with FTY720-P induces the phosphorylation of the activity-related kinases
ERK1/2 and CREB in primary cortical neurons [11] and FTY720 has been shown to upregulate
the activity-related immediate early gene c-fos in cultivated cerebellar neurons [25]. Therefore, we next
tested whether FTY720-P can also enhance c-Fos protein expression in hippocampal neurons. Therefore,
primary hippocampal cultures treated for 24h with FTY720-P or DMSO were immunostained for
c-Fos and the number of c-Fos (c-Fos+, Figure 1H, inset above) and MAP2 (MAP2+, Figure 1H, inset
below) immunoreactive neurons was quantified. Both treatment groups displayed a clear nuclear
localization of c-Fos in neurons, identified by their immune-positivity for MAP2 (Figure 1H). However,
in the control group only few neurons were positive for c-Fos in comparison to those treated with
FTY720-P (Figure 1H). Quantification of c-Fos+/MAP2+ fraction after FTY720-P treatment revealed
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a significant, almost two-fold higher number in c-Fos+ neurons than under control conditions (Figure 1I;
two-tailed unpaired t-test: t = 4.337, df = 127, p < 0.0001; DMSO: 1.000 ± 0.0856, FTY720-P: 1.975 ±
0.2174).
This observation shows the ability of a 24-h treatment with FTY720-P to upregulate c-Fos
transcription factor in primary hippocampal neurons.
2.3. Fingolimod-Phosphate (FTY720-P) Mediated Effects are BDNF-Dependent
Several studies have reported the ability of FTY720 and/or FTY720-P to positively modulate
the expression and the secretion of BDNF both in vitro and in vivo [11,12,15,26]. Deogracias et al.
(2012) showed a time-dependent increase in BDNF mRNA and protein levels with a peak after 24 h
FTY720-P application in primary cortical neurons. Interestingly, the increase in BDNF protein was
shown to be inversely correlated with the drug concentration [11]. A low dosage of FTY720 was also
reported to influence in vitro viability of neural stem cells [27] and recently, also to rescue memory
impairment in a mouse model of Alzheimer’s disease [28]. Thus, we next tested the activity of
a 5-fold lower concentration of FTY720-P in modulating the dendritic architecture of hippocampal
neurons in primary hippocampal cultures. DIV21 feGFP expressing neurons were treated for 24 h with
2 nM FTY720-P (FTY720-P_2nM) or DMSO and dendritic complexity was compared using the Sholl
analysis (Figure 2A). Interestingly, this low FTY720-P concentration also led to significant alterations
in the complexity of proximal dendrites (Figure 2A,B; two-way ANOVA F3,8418 = 33.53, p < 0.0001).
Indeed, a significantly higher number of intersections were observed, especially between 20 and
50 µm from the cell body (Figure 2A,B) compared to DMSO treated neurons. Likewise, significantly
more total intersections were computed for neurons treated with 2 nM (FTY720-P_2nM) than for
the neurons treated with DMSO (Figure 2C; one-way ANOVA F3,138 = 3.469, p < 0.05; DMSO: 243.9 ±
9.940, FTY720-P_2nM: 281.0 ± 9.429).
Figure 2. Cont.
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Figure 2. Fingolimod-phosphate (FTY720-P) regulates neuronal architecture in a BDNF-dependent
manner. (A) Representative Neurolucida tracings, used to perform the Sholl analysis of dendritic
complexity for feGFP expressing neurons treated for 24h with: DMSO (black), 2nM FTY720-P (gray),
DMSO + TrkBFc (dark blue) and 2nM FTY720-P + TrkBFc (light blue). Scale bar: 100 µm. (B) Sholl
analysis displayed as number of dendritic intersections against distance from the cell body for DMSO
(black), 2nM FTY720-P (gray), DMSO + TrkBFc (dark blue) and 2nM FTY720-P + TrkBFc (light blue) and
(C) total dendritic complexity of all treatment groups. F value in (B) refers to comparison between all
the 4 treatment groups. (D) Dendritic spine densities for DMSO (black), 2nM FTY720-P (gray), DMSO
+ TrkBFc (dark blue) and 2nM FTY720-P + TrkBFc (light blue) calculated using segments of secondary
dendritic branches as shown in (E) feGFP panel. The Syn panel displays the corresponding staining
of the pre-synaptic marker SynapsinI/II and the merge panel shows the images with overlapping
SynapsinI/II puncta (red, pre-synapse) to its matching feGFP dendrite segment (green, post-synapse).
The arrows point to coinciding puncta, indicative of mature synapse between the post and pre-synaptic
compartments. Scale bar: 5µm. (F) The graph compares the fraction of SynapsinI/II positive feGFP
labelled spines for DMSO (black), 2nM FTY720-P (gray), DMSO + TrkBFc (dark blue) and 2nM FTY720-P
+ TrkBFc (light blue). (G) Representative fields of view (FOV) of the DMSO, 2nM FTY720-P, DMSO +
TrkBFc and 2nM FTY720-P + TrkBFc treated hippocampal cultures stained for c-fos. Scale bar: 100µm.
(H) Quantification of the proportion of c-Fos expressing neurons represented as normalized fraction
for DMSO (black), 2nM FTY720-P (gray), DMSO + TrkBFc (dark blue) and 2nM FTY720-P + TrkBFc
(light blue) treated cultures. All graphs represent data as mean + SEM. Numbers in the bars show
either total number of neurons or of FOV analyzed, obtained from ≥3 sets of independent experiments.
Two-way ANOVA followed by Bonferroni post-hoc test was used in (B). For (C,D,F) and (H) one-way
ANOVA with Bonferroni post-hoc was used. Denotations for significance are * p < 0.05, ** p < 0.01,
**** p < 0.0001.
FTY720 has been shown to modulate BDNF levels in a time and concentration-dependent manner.
BDNF, which is a critical modulator of structural and functional plasticity in neurons [3], promotes
dendritic growth and branching [29,30], and regulates dendritic spine density and morphology in
mature neurons [31–33]. Therefore, we asked whether an increase in BDNF release is required for
the FTY720-P induced changes in the dendritic architecture. To achieve this aim, DIV21 primary
hippocampal cultures were treated with a either FTY720-P_2nM or TrkB receptor bodies (TrkB-Fc) or
a combination of the two for 24 h. Treatment with TrkB-Fc alone did not alter dendritic morphology
compared to the relative DMSO control as measured using Sholl analysis (Figure 2A,B; two-way ANOVA
F3,8418 = 33.53, p < 0.0001). However, when applied in combination with TrkB-Fc, a 24-h treatment with
FTY720-P_2nM failed to induce the significant modifications in the dendritic architecture observed
upon application of FTY720-P_2nM alone (Figure 2A,B). Indeed, also the increase in total intersections
upon FTY720-P_2nM treatment was completely abolished through the TrkB-Fc co-treatment and
reduced to control levels (Figure 2C; one-way ANOVA F3,138 = 3.469, p < 0.05; DMSO: 243.9 ± 9.940,
FTY720-P_2nM: 281.0 ± 9.429, TrkB-Fc: 251.8 ± 6.460, FTY720-P_2nM+TrkB-Fc: 251.0 ± 8.672). Further,
a BDNF-dependent effect of FTY720-P_2nM in regulating the number of dendritic spines was analyzed
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on secondary dendritic branches of primary hippocampal neurons. While a treatment with TrkB-Fc
alone resulted only in a mild decrease in dendritic spine density, a 24-h application of FTY720-P_2nM
significantly augmented spine density relative to the control treated neurons (Figure 2E-feGFP, D;
one-way ANOVA F3,72 = 13.66, p < 0.0001; DMSO: 1.226 ± 0.0449, FTY720-P_2nM: 1.574 ± 0.0736).
This increase was completely prevented when the FTY720-P_2nM was co-applied with TrkB-Fc
(Figure 2E-feGFP, D; one-way ANOVA F3,72 = 13.66, p < 0.0001; DMSO: 1.226 ± 0.0449, FTY720-P_2nM:
1.574 ± 0.0736, TrkB-Fc: 1.180 ± 0.0388, FTY720-P_2nM+TrkB-Fc: 1.142 ± 0.0451). To probe whether
the increase in dendritic spine density corresponds to an increase in the absolute number of functional
synapses, the cultures were immunostained for the pre-synaptic marker SynapsinI/II (Figure 2E-Syn)
and its co-localization with the dendritic spines of feGFP transfected neurons was compared between
the different treatments (Figure 2E-Merge). Across all treatment groups, the proportion of synapsinI/II
positive spines was found to be about ~57% with only a slight increase upon FTY720-P_2nM treatment
and a slight decrease upon the combined treatment with FTY720_2nM and TrkB-Fc (Figure 2E-Merge,
F; one-way ANOVA F3,72 = 1.398, p = 0.2505; DMSO: 0.5800 ± 0.0168, FTY720-P_2nM: 0.6093 ± 0.0194,
TrkB-Fc: 0.5740± 0.0267, FTY720-P_2nM+TrkB-Fc: 0.5516± 0.0183). These differences, however, did not
reach significance (Figure 2F). This constant fraction of SynapsinI/II positive, mature synapses suggest
that FTY720-P_2nM indeed increases the absolute number of functional synapses (Figure 2E-Merge, F).
In the CNS, c-fos is primarily associated with the regulation of neuronal plasticity [34] and has
been shown to be activated downstream of BDNF signaling [33,35]. Thus, we next assessed whether
the FTY720-P-induced increase in the proportion of c-Fos positive neurons also depends upon the release
of BDNF. Indeed, while treatment with 2nM FTY720-P significantly increased the number of c-Fos
positive neurons, combining it with TrkB-Fc completely prevented the enhancement in the number
of c-Fos expressing neurons (Figure 2G,H; one-way ANOVA F3,118 = 17.78, p < 0.0001; DMSO: 1.000
± 0.0414, FTY720-P_2nM: 1.350 ± 0.0454, TrkB-Fc: 1.043 ± 0.0404, FTY720-P_2nM+TrkB-Fc: 0.9985 ±
0.0340).
Taken together, these observations demonstrate that low concentrations of FTY720-P efficiently
modulate dendritic architecture and neuronal activation in mature, healthy primary hippocampal
neurons. Moreover, the TrkB-Fc co-treatment results indicate a crucial role for the release of BDNF in
mediating the effects of FTY720-P.
2.4. Non-Phosphorylated Fingolimod (FTY720) Recapitulates the Dendritic Modifications Induced by
the Phosphorylated (FTY720-P) Form
FTY720-P is the active drug form known to interact with its target S1P receptors at membrane
surfaces. However, in a clinical scenario the drug is provided in the form of non-phosphorylated
FTY720, due to its ability to cross the blood brain barrier and the lipid membrane. Therefore, we next
wanted to investigate whether the non-phosphorylated FTY720 is capable of recapitulating the effects
we observed using the phosphorylated form. Thus, mature DIV21 hippocampal cultures were treated
for 24 h with 10 nM FTY720 or the relative DMSO control. First, the dendritic complexity was analyzed
in feGFP expressing neurons using Sholl analysis (Figure 3A,B). The dendritic tree of FTY720 treated
neurons was significantly more complex than the one of the DMSO-treated counterparts (Figure 3A,B;
two-way ANOVA F1,4636 = 55.64, p < 0.0001). Accordingly, total dendritic complexity (Figure 3B;
two-tailed unpaired t-test: t = 2.277, df = 76, p < 0.05; DMSO: 330.8 ± 13.10, FTY720: 373.4 ± 13.29) as
well as total dendritic lengths (Figure 3C; two-tailed unpaired t-test: t = 2.410, df = 76, p < 0.05; DMSO:
3867 ± 142.9, FTY720: 4385 ± 159.2) showed a significant increase in the FTY720 treated group when
compared to the controls. Finally, the effect of a 24h application of FTY720 was analyzed for dendritic
spine density. Also here, FTY720 application led to a significant increase in dendritic spine density
compared to the DMSO application (Figure 3D,E; two-tailed unpaired t-test: t = 3.550, df = 77, p <
0.001; DMSO: 1.027 ± 0.0283, FTY720: 1.162 ± 0.0256).
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Figure 3. Treatment with the non-phosphorylated Fingolimod (FTY720) modulates neuronal
architecture. (A)| Representative Neurolucida tracings from feGFP positive hippocampal neurons used
for the Sholl analysis from cultures treated either with DMSO or 10nM FTY20 for 24 h. Scale bar: 100µm.
(B)| Dendritic complexity shown by the number of dendritic intersections plotted against the distance
from the soma for DMSO (black) and FTY720 (blue) treated neurons. The F value shows the statistical
comparison between the two groups. The inset graph represents total dendritic complexity upon
treatment with DMSO (black) and FTY720 (blue). (C)| Total dendritic length for DMSO (black) and
FTY720 (blue) treated neurons. (D)| Representative stretches from dendrites of eGFP transfected
hippocampal neurons showing dendritic spine protrusions, treated either with DMSO or FTY720 for
24h. Scale bar: 5µm. (E)| The graph shows dendritic spine density for DMSO (black) and FTY720 (blue)
treated neurons. (F)| Representative images of fields of view (FOV) from primary hippocampal cultures
stained with anti phospho-ERK1/2 antibody, 30 min post-application of one of the following: DMSO,
10nM FTY720, DMSO_100, 100nM FTY720, DMSO_100 + TrkB-Fc, 100nM FTY720 + TrkB-Fc or 40ng
recombinant BDNF protein as a positive control. Scale bar: 100µm. (G)| The graph displays the fraction
of pERK1/2 expressing neurons relative to the total number of MAP2+ neurons. The data is normalized
to the respective controls and compared between the different treatment groups: DMSO (black), 10nM
FTY720 (light blue solid), DMSO100 (gray), 100nM FTY720 (dark blue solid), 40ng recombinant BDNF
(magenta), DMSO100 + TrkB-Fc (gray open), 100nM FTY720 + TrkB-Fc (dark blue open). All data is
plotted as mean + SEM. Numbers in the bars show total number of neurons or FOV analyzed, obtained
from ≥3 sets of independent experiments. Two-way ANOVA followed by Bonferroni post-hoc test
was used in (B). For (B) total intersections, (C) and (E) unpaired Student’s t-test and for (G) one-way
ANOVA with Bonferroni post-hoc was used. Denotations for significance are * p < 0.05, *** p < 0.001,
**** p < 0.0001.
As shown by Deogracias et al., (2012) a 30-min FTY720-P treatment upregulated
the phosphorylation of extracellular signal-regulated kinase 1/2 (pERK1/2). We tested if this ERK1/2
phosphorylation could also be enhanced by the non-phosphorylated form. Primary hippocampal
neurons were treated with 10 nM FTY720 for 30 min and stained using antibodies against pERK1/2 and
MAP2. A clear immunofluorescence was observed in the cytoplasm and nucleus of pERK1/2 expressing
cells (Figure 3F). The number of cells positive for pERK1/2 (pERK1/2+) were quantified over the total
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of MAP2+ neurons. While at a concentration of 10 nM, FTY720 did not enhance pERK1/2 expressing
cells compared to its DMSO control (Figure 3F,G; one-way ANOVA F6,342 = 18.17, p < 0.0001; DMSO:
1.000 ± 0.0639, FTY720: 0.8692 ± 0.0558), a 10 times higher dose (100 nM), significantly increased
the number of pERK1/2+ neurons by ~80% compared to the DMSO treated cultures (Figure 3F,G;
one-way ANOVA F6,342 = 18.17, p < 0.0001; DMSO_100: 1.000 ± 0.07469, FTY720_100nM: 1.862 ±
0.1214). it is noteworthy that this increase in the pERK1/2+ fraction was comparable to the one, resulting
upon a 30 min application of recombinant BDNF protein (40 ng) (Figure 3F,G; one-way ANOVA F6,342
= 18.17, p < 0.0001; BDNF: 1.825 ± 0.1876). We then probed whether this upregulation of pERK1/2+
after 100 nM FTY720 treatment could be driven by BDNF. Therefore, the 30 min treatment with 100 nM
FTY720 was repeated in the presence of TrkB-Fc receptor bodies. TrkB-Fc co-application completely
prevented the FTY720-induced increase in the number of pERK1/2 expressing neurons. (Figure 3F,G;
one-way ANOVA F6,342 = 18.17, p < 0.0001; DMSO+TrkB-Fc: 1.000 ± 0.07079, FTY720_100nM+TrkB-Fc:
1.291 ± 0.07765).
These observations confirm that the non-phosphorylated FTY720 can indeed successfully
induce similar structural alterations in mature hippocampal neurons, as produced by its active
phosphorylated form FTY720-P. Additionally, at a higher concentration (100 nM) FTY720 acutely
upregulates phosphorylation of ERK1/2 in neurons in a BDNF-dependent fashion.
2.5. Fingolimod-Phosphate (FTY720-P) Completely Rescues the Neurite Defects Observed in Young Mecp2-/y
Neurons and Only Partially in Cdkl5-/y Neurons
Our results so far demonstrate the ability of FTY720-P to positively modulate the dendritic
architecture of hippocampal neurons in a BDNF-dependent fashion. Therefore, we wondered if
the drug could be extended for use onto mouse models for neurodevelopmental diseases characterized
by defects in neuronal architecture combined with BDNF deficiency. We selected the Mecp2-/y transgenic
mouse as a model for Rett Syndrome (RTT) caused by the expression of a dysfunctional Mecp2 protein.
In addition, Cdkl5-/y transgenic mice were used as a model for the cyclin-dependent kinase-like 5
(Cdkl5) deficiency disorder (CDD) caused by loss of function mutation in the X-linked Cdkl5. Both
diseases are associated with abnormalities in the neuronal architecture in hippocampal and cortical
neurons, including simpler dendritic arbors and reduced dendritic lengths starting already at very
early stages during development [16,17,36] [21,22,37,38].
Low-density primary cortical neurons from wild type (WT) or Mecp2 knockout (Mecp2-/y) mice were
used to test the ability of FTY720-P to rescue the impairment in the neuronal structural development
typical of RTT. The DIV1 primary cortical neurons were let develop in the presence of 10 nM FTY720-P or
DMSO for 7 days (Figure 4A schematic) before being fixed and stained for MAP2 (Figure 4B). Individual
MAP2 positive neurons with well-defined cell bodies and neuritic protrusions were selected to analyze
dendritic development using Sholl analysis (Figure 4B,C; two-way ANOVA F3,7826 = 137.4, p < 0.0001).
WT cells treated with DMSO or FTY720-P were qualitatively indistinguishable (Figure 4B). In addition,
the quantification of their neuritic complexity by Sholl analysis displayed no difference between these
two treatment groups (Figure 4C,F). The Mecp2-/y neurons, on the other hand were remarkably smaller
than WT with shorter and fewer neurites (Figure 4B). When compared to WT, Mecp2-/y neurons were
characterized by a significantly lower neuritic complexity as shown by the Sholl analysis (Figure 4C,D).
In addition, the total complexity of Mecp2-/y neurons was significantly lower compared to WT neurons
(Figure 4G; one-way ANOVA F3,560 = 43.11, p < 0.0001; WT: 41.02 ± 1.221, Mecp2 -/y: 26.13 ± 0.9886).
While WT neurons had an average number of 9.29 ± 0.2442 primary neurites arising from the cell
soma (Figure 4H; one-way ANOVA F3,564 = 6.042, p < 0.001), the Mecp2-/y neurons only had 8.30 ±
0.2507 (Figure 4H). However, Mecp2-/y neurons that developed for 7 days in the presence of FTY720-P
showed longer and more complex neurites than the control-treated counterparts (Figure 4B). This
was also true for neurite complexity which significantly increased in the FTY720-P treated group
(Figure 4C,E). Moreover, compared to the WT neurons, Mecp2 -/y neurons displayed a decrease of ~37%
in total neurite intersections which was completely rescued upon treatment with FTY720-P (Figure 4G;
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one-way ANOVA F3,560 = 43.11, p < 0.0001; Mecp2-/y + FTY720-P: 38.74 ± 1.098). Also, the average
number of primary neurites in the Mecp2-/y cultures treated with FTY720-P was restored to WT level
(Figure 4H; one-way ANOVA F3,564 = 6.042, p < 0.001; Mecp2-/y + FTY720-P: 9.752 ± 0.2274). Lastly,
the neurites of Mecp2-/y neurons were overall significantly shorter than the WT neurons (Figure 4I) and
treatment with FTY720-P completely rescued their total neurite length (Figure 4I; one-way ANOVA
F3,560 = 49.24, p < 0.0001; WT: 455.7 ± 12.93, Mecp2-/y: 279.6 ± 10.69, Mecp2-/y + FTY720-P: 417.2 ±
11.79). The FTY720-P treatment in WT cultures did not alter total neurite intersections (Figure 4G;
one-way ANOVA F3,560 = 43.11, p < 0.0001; WT: 41.02 ± 1.221, WT+FTY720-P: 42.25 ± 1.307) and length
(Figure 4I; one-way ANOVA F3,560 = 49.24, p < 0.0001; WT: 455.7 ± 12.93, WT+FTY720-P: 467.8 ± 14.95).
Figure 4. Fingolimod-phosphate (FTY720-P) completely rescues the neuronal architecture in developing
Mecp-/y cortical neurons. Young DIV7 cortical cultures from Mecp2-/y mice or littermate wild type (WT)
controls were allowed to develop for one week with either DMSO alone or with 10nM FTY720-P in
the growth medium. (A) The diagram shows the scheme of treatment from culture preparation on DIV0,
treatment from DIV1 to fixation on DIV7. (B) Micrographs showing representative fluorescent images
of DIV7 WT and Mecp2-/y cortical neurons stained for MAP2 and treated with either DMSO or FTY720-P.
Scale bar: 50 µm. Neurite complexity plotted as number of neurite intersections against the distance
from the soma for: (C) all four test groups- WT (black), WT neurons treated with 10nM FTY720-P
(gray), Mecp2-/y (dark green) and Mecp2-/y neurons treated with 10nM FTY720-P (light green). F value
for comparison between all sets is described with the graph. For better visualization of differences
between different pairs, Sholl curves are also plotted separately: (D) WT (black) and Mecp2-/y (dark
green) neurons (E) Mecp2-/y neurons treated with 10nM FTY720-P (light green) v/s DMSO controls
(dark green) and (F) WT neurons treated with 10nM FTY720-P (gray) v/s DMSO controls (black).
(G) Total intersections, (H) number of neurites and (I) total length of neurites as computed for WT
neurons treated with DMSO (black) or FTY720-P (gray) and Mecp2-/y treated with DMSO (dark green)
or FTY720-P (light green). Data in graphs is plotted as mean + SEM. Numbers in the bars show total
number of neurons analyzed for each genotype and treatment, obtained from ≥3 sets of independent
experiments. Two-way ANOVA followed by Bonferroni post-hoc test was used in A. For G,H and I
one-way ANOVA with Bonferroni post-hoc was used. Denotations for significance are *** p < 0.001,
**** p < 0.0001.
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Next, DIV 1 WT or Cdkl5-/y cortical cultures were cultured in the presence of 10 nM FTY720-P or
DMSO until DIV 7 (Figure 5A). MAP2 positive neurons from each treatment group show cell body
with several neurites of different lengths (Figure 5B). WT neurons treated with DMSO alone or with
FTY720-P displayed no difference in overall appearance (Figure 5B) and the quantification of their
neuritic complexity showed no significant difference both for the Sholl analysis (Figure 5C,F) and
their total complexity (Figure 5G; one-way ANOVA F3,669 = 10.48, p < 0.0001; WT: 45.51 ± 1.306,
WT+FTY720-P: 45.17 ± 1.393). On the other hand, neurons lacking Cdkl5 exhibited significant structural
deficits identifiable by their less complex neurite morphology and shorter neurites (Figure 5B). The Sholl
analysis revealed significantly lower complexity for Cdkl5-/y neurites in comparison to WT neurons
(Figure 5C,D; two-way ANOVA F3,11373 = 32.07, p < 0.0001). FTY720-P in the growth medium resulted
in a mild, albeit significant increase in the neurite complexity of Cdkl5-/y neurons (Figure 5C,E). While
total neuritic complexity of FTY720-P treated Cdkl5-/y neurons was only slightly higher than control
Cdkl5-/y neurons (Figure 5G; one-way ANOVA F3,669 = 10.48, p < 0.0001; Cdkl5-/y: 37.18 ± 1.104, Cdkl5-/y
+ FTY720-P: 40.63 ± 1.204), the total neuritic length was significantly enhanced (Figure 5I; one-way
ANOVA F3,670 = 10.48, p < 0.0001; Cdkl5-/y: 427.2 ± 12.53, Cdkl5-/y + FTY720-P: 478.1 ± 13.89). Although
the average number of primary neurites in Cdkl5-/y neurons was slightly lower than the WT, it was
statistically not significant (Figure 5H; one-way ANOVA F3,669 = 1.162, p = 0.3235; WT: 9.086 ± 0.3673,
Cdkl5-/y: 8.804± 0.3707, Cdkl5-/y + FTY720-P: 9.166± 0.4110). WT neurons treated with FTY720-P showed
a mild, though not statistically significant increase in the number of primary neurites (Figure 5H;
one-way ANOVA F3,669 = 1.162, p = 0.3235; WT: 9.086 ± 0.3673, WT+FTY720-P: 9.780 ± 0.3909) and
did not show any changes in their total neurite length (Figure 5I; one-way ANOVA F3,670 = 10.48,
p < 0.0001; WT: 526.1 ± 14.77, WT±FTY720-P: 514.7 ± 15.48).
Figure 5. Fingolimod-phosphate (FTY720-P) shows mild rescue in neuronal morphology of young
cortical neurons from Cdkl5-/y mice. Young DIV7 cortical cultures from mice carrying a Cdkl5-/y mutation
or littermate wild type (WT) controls, were grown in presence of DMSO alone or 10 nM FTY720-P in
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the growth medium. (A) The diagram shows the scheme of treatment from culture preparation on DIV0,
treatment from DIV1 to fixation on DIV7. (B) Micrographs display representative DIV7 MAP2 positive
cortical neurons. The WT and Cdkl5-/y neurons were both treated either with DMSO or FTY720-P.
Scale bar: 50 µm. (C) Neurite complexity for both genotypes treated with DMSO and FTY720-P was
analyzed and plotted as number of neurite intersections against the distance from the soma. F value for
comparison between the four sets is described in the graph. The Sholl curve for following genotype
and treatment sets are also displayed separately (D) WT (black) v/s Cdkl5-/y (dark red), (E) Cdkl5-/y
neurons treated with 10nM FTY720-P (rosa) v/s DMSO controls (dark red), (F) WT neurons treated with
10nM FTY720-P (gray) v/s DMSO controls (black). (G) Total intersections, (H) number of neurites and
(I) total length of neurites as computed for WT neurons treated with DMSO (black) or FTY720-P (gray)
and Cdkl5-/y neurons treated with DMSO (dark red) or FTY720-P (rosa). Data in graphs is represented
as mean + SEM. Numbers in the bars show total number of neurons analyzed for each genotype
and treatment, obtained from ≥3 sets of independent experiments. Two-way ANOVA followed by
Bonferroni post-hoc test was used in (A). For (G,H) and (I) one-way ANOVA with Bonferroni post-hoc
was used. Denotations for significance are * p < 0.05, **** p < 0.0001.
In conclusion, these results illustrate that the deficiency of Mecp2 and Cdkl5 protein respectively
leads to severely stunted growth of immature developing cortical neurons as seen by reduction in
neurite length and complexity. These defects can be entirely rescued by FTY720-P application into
the growth medium for Mecp2-/y neurons and only partially for Cdkl5-/y neurons.
3. Discussion
Our results describe a role of the immunomodulatory drug Fingolimod in modulating the dendritic
architecture of healthy mature primary hippocampal neurons. Indeed, Fingolimod application to
hippocampal primary neurons results in a significant increase both in dendritic complexity and in
dendritic spine density, associated to a higher proportion of mature, mushroom-like spines. Moreover,
we show that a treatment with Fingolimod is able to prevent the structural defects described in
hippocampal neurons from the mouse models of two neurodevelopmental disorders, namely Rett
syndrome and Cdkl5 deficiency disorder.
3.1. Fingolimod Regulates Neuronal Architecture and the Expression of Activity-Related Genes in Healthy
Mature Neurons in a BDNF-Dependent Manner
Fingolimod crosses the blood brain barrier and accumulates within the brain where, binding
to S1PRs exerts a series of direct functions on CNS cells including enhanced neuroprotective effects,
reduced inflammation and improvement of neuronal pathology in different neurological disorders.
Moreover, Fingolimod rescues the cognitive impairment and associated dendritic spine pathology
observed in mouse models of Alzheimer and Huntington disease [12–14] indicating that, at least in
part, the beneficial effects of Fingolimod may derive from its ability to modulate neuronal architecture.
However, very little is currently known about the possible effects of Fingolimod in modulating
the dendritic and spine architecture of healthy neurons. We show here that Fingolimod application to
primary hippocampal neurons results in increased spine density, associated with a higher proportion
of mushroom-like, mature spines identified by their positivity for SynapsinI/II. While application of
Fingolimod has been previously shown to promote neurite outgrowth in developing neurons [25], we
show that this effect also extends to mature healthy hippocampal neurons, showing an increase in
dendritic complexity after treatment. While these observations in vitro do not allow us to conclude
that a similar effect could be observed in vivo, they do indicate a role for Fingolimod in modulating
dendritic and spine architecture to promote neuronal connectivity within primary hippocampal cultures
and are supported by previous reports showing an increase in network activity after Fingolimod
application [11].
Several lines of evidence indicate that Fingolimod promotes BDNF synthesis and secretion both
in vivo and in vitro [11–13,15]. Moreover, BDNF has been shown to modulate dendritic and spine
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architecture in an age-dependent manner [3,33]. Here, we show that co-application of the BDNF
scavenging TrkB receptor bodies completely prevents the increase in dendritic complexity, spine
density and maturation observed upon Fingolimod-P treatment in hippocampal primary neurons
indicating the requirement for BDNF secretion in this context. Indeed, several in vitro studies support
a role for BDNF signaling in modulating the dendritic architecture during development [3,33,39] and
in regulating dendritic spine density and morphology in mature hippocampal neurons [31,32]. We
report similar observations on dendritic complexity, spine density and spine morphology of mature
hippocampal neurons upon Fingolimod application. It is noteworthy, that although the effects observed
upon treatment in mature, healthy neurons are relatively mild they are significant and consistent in
their manner of expression. Indeed, Fingolimod specifically increases the complexity of the proximal
dendritic tree. A specific effect on proximal dendrites has been previously described in cortical neurons
overexpressing BDNF [29] and after exogenous BDNF treatment in cultured hippocampal neurons [30].
However, while in our study Fingolimod affects mature neurons already after 24 h of treatment,
the effects of exogenous BDNF application required days [30]. While a clear effect of the exogenous
application of BDNF in modulating dendritic spine density in hippocampal neurons could be observed
in some studies [31,32], our laboratory failed to reproduce it [33], possibly due to differences in culture
conditions. However, in the current study we observe a significant, BDNF-dependent increase in
dendritic spine density upon Fingolimod treatment. This observation suggests a higher efficacy of
the Fingolimod-induced release of endogenous BDNF compared to its exogenous application, possibly
due to a requirement for a specific action at the release site rather that a global effect, as per bath
application. On the other hand, it should be noted that previous studies did not observe a regulation
of BDNF synthesis upon Fingolimod treatment in vivo [11] indicating the need for further studies.
The effects of BDNF on dendritic spine density have been show to occur in an activity-dependent
manner [33] and the positive modulation of dendrite architecture by BDNF occurs via
the activity-dependent expression of the cAMP response element-binding protein (CREB) [30].
Interestingly, an increase in the phosphorylation of CREB and of network activity was observed
in Fingolimod treated cortical cultures [11] suggesting that the structural changes upon its application,
could be mediated via an increase in neuronal activity and CREB phosphorylation. This increased
activity is likely since we show a significantly higher number of c-Fos expressing neurons upon
Fingolimod application. The immediate early gene c-fos is known to be upregulated upon membrane
depolarization via CREB phosphorylation and is a commonly used marker for recently activated
neurons [40]. Such a sustained increase in c-Fos positive neurons, as seen 24 h after the beginning
of Fingolimod treatment could support a positive BDNF-feedback loop and thus contribute to
the structural alterations. Indeed, c-fos is known to participate in a positive feedback loop downstream
of TrkB signaling promoting BDNF expression [41]. Finally, our data show also in hippocampal neurons
an increase in the phosphorylation of the extracellular signal-regulated kinase 1/2 (ERK1/2) in treated
cultures as previously reported for cortical neurons [11]. The increase in the proportion of pERK1/2+
cells in Fingolimod treated cultures was comparable to the one observed in BDNF treated ones and was,
as for c-Fos expression reduced to control levels upon co-treatment with TrkB-Fc receptor bodies again
supporting the necessity of BDNF secretion for the Fingolimod induced effects in hippocampal neurons.
3.2. Fingolimod Treatment Rescues the Impaired Neurite Outgrowth in Cortical Neurons in Two X-linked
Neurodevelopmental Disorders
While a growing body of evidence supports the benefits of modulating BDNF-TrkB signaling in
several neurological conditions, its inability to cross the blood brain barrier as well as the need for
temporally and spatially regulated BDNF signaling limit its direct use in therapy. Alternative methods
for modulating BDNF levels within specific brain areas include drug-induced BDNF expression. Among
these drugs Fingolimod has been successfully used to rescue the cognitive impairment observed in
many neurological diseases. However, still, little is known about the cellular mechanisms underlying
its beneficial action. Our study adds to this notion, by analyzing the cellular effects of Fingolimod
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in two X-linked neurodevelopmental disorders, namely Rett syndrome (RTT) and Cdkl5 deficiency
disorder (CDD). Both disorders show severe anomalies in neuronal structures both in patients [42]
and in the relative mouse models: Mecp2 [17] or Cdkl5 knockout mice [37]. Our results confirmed
the altered neuronal phenotype in developing cortical neurons derived from Mecp2-/y as well as Cdkl5-/y
mice. The knockout neurons were found to be significantly simpler in complexity and shorter when
compared to their relative controls. Fingolimod application completely rescued the impairment in
neurite growth in Mecp2-/y cortical neurons. While our results cannot exclude a BDNF-independent
activity of Fingolimod, it is interesting that the onset of RTT-like phenotypes in Mecp2 knockouts is
associated with the absence of the typical increase in BDNF levels observed postnatally. The bdnf /Mecp2
double knockout shows exacerbated symptoms and an earlier disease onset [18], indicating a link
between the impaired BDNF expression and the RTT pathology. Accordingly, promoting BDNF/TrkB
signaling via Fingolimod injection significantly improved motor behavior and the average lifespan of
Mecp2 mutant mice [11]. The current results support the hypothesis that Fingolimod might rescue
neuronal structure in Mecp2-/y mice, possibly in a BDNF-dependent manner. It is important to
note that our findings indicate benefits of Fingolimod by rescuing the typical defects in neuronal
architecture at an early developmental stage. However, whether a rescue of the morphological
phenotype could be obtained in fully developed neurons in juvenile or adult knockout animals needs
further investigation. While application of a TrkB agonist has been shown to rescue both functional
and structural impairments in the perirhinal cortex of Cdkl5-/y mice [23], little is known about the role
of BDNF in the pathology of CDD in contrast to RTT. Our results show that application of Fingolimod
results in a partial rescue of the structural impairments observed in Cdkl5-/y cortical neurons. While
our current results cannot exclude an effect of Fingolimod independent of its ability to promote BDNF
release, the partial rescue in Cdkl5-/y could be explained by looking at the position of BDNF along
the Mecp2 and Cdkl5 downstream signaling pathways. Indeed, while Mecp2 functions upstream
of BDNF to regulate its activity-dependent transcription [43], Cdkl5 lies downstream of BDNF-TrkB
signaling to activate Rac1 [44]. Thus, while modifying endogenous BDNF levels using Fingolimod
may compensate for its reduced levels in Mecp2-/y neurons, it may not rescue the effects of the loss of
the intermediate signaling protein in Cdkl5-/y neurons. The partial rescue observed possibly indicates
an indirect, neuroprotective action of Fingolimod in this context.
In summary, the results of our study can be divided in two main independent parts. On one side,
our study reports specific BDNF-dependent effects of the immunomodulatory drug Fingolimod in
modulating the dendrite architecture of mature, healthy CNS neurons. In addition, our observations add
to the understanding regarding the cellular mechanisms underlying the positive effects of a Fingolimod
treatment in two highly relevant X-linked neurodevelopmental disorders.
4. Materials and Methods
4.1. Animals
All studies including wild-type (WT) mice were done using C57Bl/6J mice bred in the mouse
facility of the TU Braunschweig. The Mecp2 null mouse strain, originally purchased from Jackson
Laboratories (003890 B6.129P2(C)-Mecp2<tm1.1Bird>/J), was backcrossed and maintained on a clean
CD1 background [45]. The Cdkl5 null mouse strain was originally kindly donated by Dr Elisabetta
Ciani (University of Bologna). C57BL/6 Cdkl5 heterozygous females were crossed with CD1 WT male
mice for at least ten generations. Timed-pregnant females were generated by overnight crossing wild
type or hemizygous CD1 males with Mecp2+/− or Cdkl5+/- CD1 females. The Mecp2 and the Cdkl5 null
mutant strains were bred in the laboratory of Prof. Nicoletta Landsberger where the experiments
with these mice were performed (University of Milan, Milan). Genotypes were assessed by PCR on
genomic DNA purified from tails to distinguish knockouts and littermate WT controls. Mice were
housed on a 12 h light/dark cycle in a temperature-controlled environment (21 ± 2 ◦C) with food and
water provided ad libitum. All procedures concerning animals were performed in accordance with
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the European Union Communities Council Directive (2010/63/EU) and were approved by the animal
welfare representative of the TU Braunschweig and the LAVES (Oldenburg, Germany, Az. §4 (02.05)
TSchB TU BS) as well as by the Italian Council on Animal Care, the Italian Government decree No.
210/2017 and the San Raffaele Scientific Institutional Animal Care and Use Committee in accordance
with the Italian law.
4.2. Reagents and Stock Solutions
Fingolimod hydrochloride: FTY720 (USBiological, Swampscott, MA, USA) and
Fingolimod-Phosphate: FTY720-P (Cayman chemical, Ann Arbor, MI, USA), were dissolved in
Dimethyl sulfoxide (DMSO, anhydrous; ThermoFisher Scientific,Waltham, MA, USA). FTY720-P
required gentle sonication for 2–5 min for dissolution. Stock solution for FTY720 (100mM), FTY720-P
(1mM) and control DMSO vials were stored at −20 ◦C until used. Recombinant Human BDNF protein
(R&D systems, Minneapolis, MN, USA) was dissolved in sterile PBS with 0.1% BSA at a concentration
of 50 ng/µL. BDNF scavenging TrkB-Fc receptor bodies (Recombinant Human TrkB-Fc Chimera, R&D
systems, Minneapolis, MN, USA) were reconstituted in sterile PBS at 50 µg/mL. BDNF and TrkB-Fc
were stored at −70 ◦C until used.
4.3. Primary Hippocampal Cultures
Primary mouse hippocampal and cortical cultures were prepared on embryonic day 18.
The pregnant female was rapidly killed by cervical dislocation, the abdomen was sterilized, and
the embryos were collected under sterile conditions. Post-decapitation the embryonic brains were
quickly isolated and immersed in ice-cold Gey’s balanced salt solution supplemented with glucose and
with a pH adjusted to 7.3. The hippocampi and/or cortices were dissected, incubated in Trypsin-EDTA
(Sigma-Aldrich, St. Louis, MO, USA) at 37 ◦C for 30 min and further dissociated mechanically using
a Pasteur pipette. The cells were re-suspended in Gibco Neurobasal medium ( ThermoFisher Scientific,
Waltham, MA, USA) supplemented with 2% B27(Invitrogen, Carlsbad, CA, USA) (v/v), 10% N2 and
0.5 mM Gibco glutamax ( ThermoFisher Scientific, Waltham, MA, USA) and plated at high (7 ×
104/cm2) or low density (3.5 × 104/cm2) on 12 mm glass coverslips previously coated with poly-L-lysine
(Sigma-Aldrich, St. Louis, MO, USA). The cultures were incubated at 37 ◦C, 5% CO2 and 95% O2 until
usage. Medium change was done once a week by replacing 20% of the medium. The C57Bl/6J WT
hippocampal cultures were fixed at DIV21 whereas Mecp2 and Cdkl5 cortical cultures, at DIV7.
4.4. Transfection and Treatments
At DIV20, mature hippocampal neurons were transfected using Lipofectamine2000 (ThermoFisher
Scientific, Waltham, MA, USA) as per manufacturer’s instructions. 0.8µg farnesylated-eGFP (Clonetech:
pEGFP-F, Mountain View, CA, USA) expressing plasmid were used for each well. Then, 24-h after
transfection, the cells were treated with 2, 10, or 100 nM Fingolimod phosphate (FTY720-P) or 10 and
100 nM Fingolimod (FTY720) and the respective DMSO controls diluted into Neurobasal medium
without supplements. All FTY720-P concentrations used in the study were in the nM range. Since
the physiological levels of Fingolimod crossing the blood brain barrier and accumulating in local
neuronal vicinity cannot be clearly estimated, our dosage selection was based on a previous report by
Deogracias et al. (2012). They showed nM ranges of FTY720-P to maximally enhance BDNF levels
(2-fold) in cortical cultures. This effect however was reduced when the drug concentration reached µM
range. In some experimental sets DMSO and FTY720-P (2 nM) treated cultures were co-treated with
TrkB-Fc receptor bodies (500 ng/mL). For pERK1/2 experiments, BDNF (40 ng/mL) treatment was used
as a positive control. The cells were fixed 24 h or, for pERK 30 min after treatment. Mecp2 and Cdkl5
knockout cortical cultures were treated starting at DIV1 by adding 100 µL of fresh Neurobasal medium
with supplements containing either 10nM FTY720-P or DMSO to the wells and were fixed at DIV7.
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4.5. Immunocytochemistry
The cultured cells were fixed for 10 min in ice cold-Paraformaldehyde (4% in PBS) and washed
3 times with PBS. Permeabilization and blocking of unspecific binding sites was done at room
temperature (RT) for 1 h with PBS containing 0.2% Triton X-100 (Sigma-Aldrich, St. Louis, MO,
USA) and 1.5% Normal Goat Serum (NGS, ThermoFisher Scientific, Waltham, MA, USA). Next,
the cells were incubated overnight with primary antibodies diluted in 1.5% NGS + 0.2% Triton X-100
containing PBS at 4 ◦C on a rocker. The following primary antibodies were used: mouse anti-MAP2
(1:1000, Sigma-Aldrich, St. Louis, MO, USA)), rabbit anti-cFos (1:10,000, Synaptic systems, Goettingen,
NI, Germany), rabbit anti-Phospho-MAPK/Erk1/2 (1:1000, Cell signaling technology, Danvers, MA,
USA), rabbit anti- SynapsinI/II (1:1000, Millipore, Burlington, MA, USA). Secondary antibodies were
diluted 1:500 in PBS in varying combinations: anti-rabbit IgG, anti-mouse IgG conjugated with
appropriate cyanine fluorophores Cy2/Cy3 or Cy5 (Jackson ImmunoResearch Labs, West Grove, PA,
USA). The secondary antibody incubation was done for 2h at RT on a rocker. Finally, the cultures
were counterstained with 4′,6-diamidino-2-phenylindole (DAPI) diluted 1:1000 in PBS for 10 min.
The coverslips were then washed with PBS and mounted onto glass slides using anti fading Fluoro-Gel
embedding medium (Electron Microscopy Sciences, Hatfield, PA, USA).
4.6. Image Acquisition and Analysis
Fluorescence microscopy was performed using a Zeiss Axioplan2 microscope equipped with
an ApoTome module (Carl Zeiss AG, Oberkochen, BW, Germany), 10× (NA 0.3), 20× (NA 0.8) and
63× (oil, NA 1.4) objectives along with a Zeiss AxioCam MRm camera. For Sholl analysis [46], single
feGFP transfected neurons were imaged using a 10× objective. A healthy neuron was identified by
a well-defined cell body and absence of irregular membranous protrusions around the soma. Dentate
gyrus cells, readily identifiable via their smaller cell body and thicker, shorter dendrites were excluded
from the analysis. The neuronal images were subsequently imported into the Neurolucida 6 software
(MicroBrightField, Williston, VT, USA), the dendritic trees were traced and thereafter their complexity
was analyzed using Neurolucida explorer by quantifying the number of intersecting dendrites at every
10 µm incremental step, starting at the cell body. The total dendritic complexity, as the sum of all
dendritic intersections and total dendritic length were also calculated for each cell. Spatially isolated
and non-overlapping secondary dendrites were selected for spine density analysis and classification.
These were imaged using a 63× (oil, NA 1.4) objective and z-sectioned at 0.5 µm increments using
the ApoTome module for structured illumination. Dendritic spine density was quantified by dividing
the number of dendritic spines counted with ImageJ (NIH, Bethesda, MD, USA) per the length in µm
of the analyzed dendritic segment. Dendritic spines were classified as previously described [24] based
on their length (from spine base at dendrite to spine head tip: Spinelen), head width (Headmax) and
neck width (Neckmin). These factors were measured manually for individual spines using ImageJ and
the spines were sorted into different subtypes based on the following criteria:
Spinelen ≤ 1µm & Headmax/Neckmin ≤ 1 µm : Stubby
Spinelen > 1µm & Headmax/Neckmin < 1.5 µm : Thin
Spinelen ≥ 3µm & Headmax/Neckmin ≤ 1 µm : Filopodia
Headmax/Neckmin ≥ 1.5 µm : Mushroom
In some experimental sets, additional immunolabeling for SynapsinI/II was performed.
The proportion of the co-localization between immunoreactive SynapsinI/II positive puncta and
feGFP-labelled dendritic spines was analyzed using ImageJ (NIH). A feGFP- labelled spine (green) was
considered co-localized with SynapsinI/II puncta (red), when a resulting yellow punctum was observed
within the same focal plane or two planes above and below. Furthermore, quantification of c-Fos (Cy3)
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and pERK (Cy3) immunopositivity was done over MAP2+ (Cy2) neurons: neurons were imaged with
10× (NA 0.3) objective under different fluorescent channels. In DIV7, low density cultures, isolated
cells were identified based on their MAP2 staining to avoid cells with overlapping neurites. With 20×
(NA 0.8) objective, neurons were imaged and analyzed for neurite morphology using Sholl analysis.
The analysis was always done by an experimenter blinded for the different genotypes and treatments.
4.7. Data Representation and Statistics
Each treatment was performed in duplicate or triplicate for each experimental set and data from
at least three sets of independent experiments were grouped together in Microsoft Excel (Microsoft
Corporation, Redmond,WA, USA). For plotting the graphs and performing the appropriate statistical
tests, the data sets were imported into Prism 6 (GraphPad Software Inc, San Diego, CA, USA ). Unless
otherwise mentioned, all data in the graphs are represented as mean +SEM. For comparing only
two treatment groups a two-tailed unpaired Student’s t-test was used. The comparison of more
than two experimental groups was done by using a one-way ANOVA followed by a Bonferroni’s
multiple comparisons post-hoc test. For Sholl analysis measurements, a regular two-way ANOVA was
performed followed by a Bonferroni’s multiple comparisons post-hoc test. Significance was considered
for p value < 0.05.
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